10 Countries With The Highest Life Expectancy
Translation Desk
Last Updated:
Top countries with highest life expectancy: Monaco (87 years), Hong Kong (85.8), Macau (85.5), Japan (85), and Liechtenstein (84.8)
The dream of living a long, fulfilling life has remained a timeless human aspiration. A happy family, the laughter of grandchildren, a peaceful retirement, and a healthy old age—these are images many of us hope will define our later years.
In recent decades, remarkable advancements in medicine, technology, and public health awareness have led to a significant increase in global life expectancy. However, only a select group of countries have achieved exceptional progress in this area. In these nations, citizens are living well beyond the age of 84 on average, offering powerful examples for the rest of the world.
Below are the top 10 countries with the highest life expectancy, based on global health statistics:
Monaco – 87 years: Nestled on the French Riviera, Monaco tops the global list. The nation's enviable longevity is attributed to a combination of superior healthcare, a peaceful and clean environment, a Mediterranean diet, and regular physical activity.
Hong Kong – 85.8 years: In Hong Kong, walking is a way of life, and the typical diet is rich in seafood and vegetables. The region benefits from free healthcare, top-tier hospitals, and proactive public health initiatives.
Macau – 85.5 years: A special administrative region of China, Macau features a robust healthcare infrastructure and a cultural emphasis on traditional diets and staying active, even in old age.
Japan – 85 years: Japan, long celebrated for the longevity of its citizens—especially women—relies on a nutrient-rich diet, daily physical activity, community support, and world-class medical care.
Liechtenstein – 84.8 years: This small European nation offers its residents clean air, natural surroundings, and a high standard of living, all contributing to their extended lifespan.
Italy – 84.2 years: The heart of the Mediterranean diet, Italy's traditional meals of olive oil, vegetables, fruit, and seafood, are coupled with close-knit family structures and a generally relaxed pace of life.
Vatican City – 84.2 years: Despite its tiny size, Vatican City enjoys a low-stress, serene environment that promotes long and peaceful lives for its residents.
South Korea – 84.1 years: South Korea stands out for its preventive health education, active ageing programmes, and a diet that includes fermented foods, seafood, and vegetables, all of which support well-being.
What These Countries Teach Us About Longevity
A close look at these nations reveals a pattern:
These factors consistently emerge as the key for a longer life. While genetics may play a role, many longevity boosters are well within our control. Simple adjustments to diet, physical activity, and mental well-being can have a profound impact. By following the example of these countries, individuals and societies alike can take meaningful steps towards healthier, longer lives.
First Published:
April 25, 2025, 16:26 IST
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
15 hours ago
- Economic Times
Cheaper cancer care therapy earns big bucks for pharma company
India's cell and gene therapy pioneer ImmunoAct has turned profitable in its first full year of operations, a rare feat in the country's emerging startup landscape where research-based pharma enterprises encounter serious scale and cash flow challenges. ImmunoACT, in which Hyderabad-based drugmaker Laurus Labs has roughly 34% equity stake, saw revenues of ₹62 crore with a profit before tax of ₹12 crore in FY25, according to sources. The year before, ImmunoAct had revenues of ₹11 crore. Founded by immunologist Rahul Purwar in 2013, ImmunoACT was spun off from the department of bioengineering department of IIT Bombay in 2018. ImmunoACT's NexCAR19 is the first indigenously developed breakthrough cancer CAR-T (chimeric antigen receptor T-cell) therapy approved by India's central drug regulatory agency in October 2023. NexCAR19 was formally launched in India in April 2024 at a price ~90% cheaper than its US and European counterparts like Novartis and Gilead, making it far more affordable for India and low-and-middle income countries, on its potential approval. So far, the therapy has been infused in over 350 patients across 70 hospitals in India. In CAR-T treatment, the patient's immune cells are extracted and through a maze of re-engineering processes infused back to recognize and kill cancer cells, giving a longer remission to patients as compared to the conventional options like immunotherapy or bone marrow transplants. The therapy is used when all other options are CAR-T dose (one-and-done infusion) costs around ₹30 lakh, which was initially priced at ₹42 lakh, and is expected to see a further decline as demand picks ImmunoACT has recently appointed former managing director of Roche India V Simpson Immanuel as its strategic Purwar added, "We needed someone who understands not just the commercial landscape, but also the nuances of innovation, patient access, and global expansion." Earlier this year, Immuneel Therapeutics, backed by leading names like Kiran Mazumdar-Shaw and globally renowned oncologist Siddhartha Mukherjee secured approval for Qartemi, its cell therapy for adult B-cell non-Hodgkin Lymphoma, in India. Companies like Cipla, Dr Reddy's Labs and Bharat Biotech are investing heavily in new CAR-Ts. Globally, CAR-Ts are at the frontiers of a range of cancer treatments, attracting billions of dollars in investments from large drugmakers. The market for such therapies is expected to touch $134 billion by 2034 from around $10 billion at present.
Time of India
16 hours ago
- Time of India
Cheaper cancer care therapy earns big bucks for pharma company
ImmunoAct, an Indian cell and gene therapy company, has achieved profitability in its first full year, generating ₹62 crore in revenue and ₹12 crore in profit before tax in FY25. Its NexCAR19, an affordable CAR-T therapy, has been administered to over 350 patients across India. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads India's cell and gene therapy pioneer ImmunoAct has turned profitable in its first full year of operations, a rare feat in the country's emerging startup landscape where research-based pharma enterprises encounter serious scale and cash flow in which Hyderabad-based drugmaker Laurus Labs has roughly 34% equity stake, saw revenues of ₹62 crore with a profit before tax of ₹12 crore in FY25, according to sources. The year before, ImmunoAct had revenues of ₹11 by immunologist Rahul Purwar in 2013, ImmunoACT was spun off from the department of bioengineering department of IIT Bombay in NexCAR19 is the first indigenously developed breakthrough cancer CAR-T (chimeric antigen receptor T-cell) therapy approved by India's central drug regulatory agency in October was formally launched in India in April 2024 at a price ~90% cheaper than its US and European counterparts like Novartis and Gilead, making it far more affordable for India and low-and-middle income countries, on its potential approval. So far, the therapy has been infused in over 350 patients across 70 hospitals in CAR-T treatment, the patient's immune cells are extracted and through a maze of re-engineering processes infused back to recognize and kill cancer cells, giving a longer remission to patients as compared to the conventional options like immunotherapy or bone marrow transplants. The therapy is used when all other options are CAR-T dose (one-and-done infusion) costs around ₹30 lakh, which was initially priced at ₹42 lakh, and is expected to see a further decline as demand picks ImmunoACT has recently appointed former managing director of Roche India V Simpson Immanuel as its strategic Purwar added, "We needed someone who understands not just the commercial landscape, but also the nuances of innovation, patient access, and global expansion."Earlier this year, Immuneel Therapeutics, backed by leading names like Kiran Mazumdar-Shaw and globally renowned oncologist Siddhartha Mukherjee secured approval for Qartemi, its cell therapy for adult B-cell non-Hodgkin Lymphoma, in India. Companies like Cipla , Dr Reddy's Labs and Bharat Biotech are investing heavily in new CAR-Ts are at the frontiers of a range of cancer treatments, attracting billions of dollars in investments from large drugmakers. The market for such therapies is expected to touch $134 billion by 2034 from around $10 billion at present.
Hans India
a day ago
- Hans India
Indian genetics demand tailored obesity solutions, finds new global study led by CSIR-CCMB
A recent international study led by the Centre for Cellular and Molecular Biology (CSIR-CCMB) in Hyderabad has revealed that lifestyle-based interventions or targeted nutrient supplementation could be more effective for Indians at genetic risk of obesity than generic global approaches. The research highlights a significant genetic variation in obesity risk between Indian and European populations, underlining the need for culturally and biologically relevant health strategies. The study, spearheaded by Dr. Giriraj Ratan Chandak and his team at CSIR-CCMB, forms part of a major global research initiative involving 600 scientists from over 500 institutions. Drawing on genetic data from more than 5 million individuals, including inputs from the GIANT consortium and 23andMe, the study explored how genetic and lifestyle factors combine to influence obesity. A key finding of the study was that the widely used Polygenic Risk Score (PRS)—a genetic test designed to predict obesity—performs more accurately in populations of European ancestry than in those with South Asian ancestry, including Indians. While many obesity-related gene variants identified in Europeans were also tested on Indian samples, most showed limited predictive power, reaffirming the unique nature of Indian genetic makeup. To dig deeper, the researchers analysed genome data from Indian individuals—both diabetics and non-diabetics—who have been monitored over the past two decades. They discovered a distinct pattern of central or abdominal obesity in Indians, unlike the more generalized obesity seen in Western populations. Interestingly, individuals with higher genetic risk for obesity responded better to lifestyle interventions like diet and exercise. However, they were also more prone to weight regain once those interventions ended. 'This finding mirrors earlier studies on height, where European genetic markers had limited applicability to Indians. It appears that diet, nutrition, and environment might play an equally, if not more, critical role in determining obesity in Indians,' said Dr. Chandak. Using Indian genomic data, the team developed a more region-specific PRS to model obesity risk and improve early detection, especially among children. The refined model can predict adulthood obesity by the age of five, making it twice as effective as older models. This breakthrough could enable early preventive measures among genetically vulnerable children, a move that could significantly reduce the burden of obesity-linked diseases such as diabetes and hypertension in India. 'This is not just a test. It's a predictive tool for proactive care,' said Assistant Professor Roelof Smit from the NNF Centre for Basic Metabolic Research at the University of Copenhagen and lead author of the global study, published in Nature Medicine. 'By identifying risk early, especially before lifestyle habits solidify, we can dramatically improve health outcomes.' The findings reiterate that while genetics do play a role, customised lifestyle strategies are critical for Indian populations. The future of obesity prevention in India may rest in precision medicine, where treatment plans are based not just on global data but on uniquely Indian insights.
